TLMdX from AASLD 2020
November 13—16, 2020
While we are gathering our agenda, we invite you to subscribe to be notified when this event page is available
Saturday, Nov 14, 2020
Our Surfers Discussed The Following Papers and Sessions on Day 2
Today’s Episode Is Sponsored By
Roger Green — 1662
ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN A LARGE COHORT OF NASH PATIENTS WITHOUT CIRRHOSIS — ZOBAIR YOUNOSSI
Donna Cryer — 0060
CLINICIAL CHARACTERISTICS USED FOR MACHINE LEARNING IDENTIFICATION OF FAST PROGRESSORS AMONG PATIENTS WITH NASH — JOERN SCHATTENBERG.
Dr. Stephen Harrison — 1710 A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
Manal F. Abdelmalek — 0057
GEMS, A Genetic Metabolic Staging Predicting the Outcome of NAFLD — GRAZIA PENNISI
Surfing The NASH Tsunami Podcast Day 2
Sunday, Nov 15, 2020
Our Surfers Discussed The Following Papers and Sessions on Day 3
Louise Campbell MSc AP — 0090 CIRRHOSIS REGRESSION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
Roger Green & Louise Campbell MSc AP — 0086 THE NATURAL HISTORY OF LEAN NONALCOHOLIC FATTY LIVER DISEASE: A LONGITUDINAL US POPULATION STUDY
Roger Green — 072 FINAL ANALYSIS OF A 24-WEEK, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ALDAFERMIN (NGM282) IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
Surfing The NASH Tsunami Podcast Day 3
Monday, Nov 16, 2020
Our Surfers Discussed The Following Papers and Sessions on Day 4
Dr. Stephen Harrison — LP23
RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE3 WEEK 72 ITNERIM SURROGATE EFFICACY ANALYSIS
Louise Campbell MSc AP — 141
DIET RELATED MORTALITYARY AMONG NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): DATA FROM THE GLOBAL BURDEN OF DISEASE (GBD) 2017
Roger Green —
L03 – ALDAFERMIN (NGM282) PRODUCES GREATER ANTI-FIBROTIC RESPONSE IN PATIENTS WITH NONALCOHOLIC STREATOHEPATITIS AND ADVANCED FIBROSIS
&
0143
ONSET OF OBESITY-RELATED PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE (PNAFLD) DURING PREPUBERTAL GROWTH EXACERBATES HEPATIC INFLAMMATION AND MITOCHONDRIAL DNA DEPLETION TO ACCELERATE LIVER INJURY
Mary E. Rinella, MD. — 010
EFFICACY AND SAFETY OF SUBCUTANEOUS SEMAGLUTIDE ONCE-DAILY VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
Surfing The NASH Tsunami Podcast Day 4
Episode 38
The Day After TLMdX 2020: Wrapping Up with The View from Across the Atlantic
Prof. Dr. Jörn M. Schattenberg and Vlad Ratziu join the Surfers for our wrap-up episode for TLMdX 2020. Joern focuses on a diabetes poster demonstrating the path of drug efficacy over a three-year period, while Vlad focuses on the successful Phase 2 trial of the pan-PPAR lanifibranor. The group also asks why placebo response varies so much between studies and whether the ratio of F2:F3 patients may be a factor. Finally, the Surfers focuses on what they consider the biggest lessons emerging from the meeting.Available In Your Favorite Podcast App:
